Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
6.01
-0.23 (-3.69%)
At close: May 18, 2026, 4:00 PM EDT
6.04
+0.03 (0.50%)
After-hours: May 18, 2026, 7:29 PM EDT
Xeris Biopharma Holdings Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Xeris Biopharma Holdings stock has a consensus rating of "Strong Buy" and an average price target of $11.29. The average 1-year stock price forecast is 87.85% higher than the current stock price, while the lowest is $8.00 (+33.11%) and the highest is $18 (+199.50%).
Price Target: $11.29 (+87.85%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 2, 2026.
Analyst Ratings
The average analyst rating for Xeris Biopharma Holdings stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +66.39% | Mar 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +66.39% | Jan 9, 2026 |
| Barclays | Barclays | Buy Initiates $9 | Buy | Initiates | $9 | +49.75% | Dec 9, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $18 | Buy | Maintains | $18 | +199.50% | Nov 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +66.39% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
391.54M
from 291.85M
Increased by 34.16%
Revenue Next Year
481.13M
from 391.54M
Increased by 22.88%
EPS This Year
0.12
from 0.00
Increased by 3,625.69%
EPS Next Year
0.35
from 0.12
Increased by 196.35%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 409.2M | 528.2M | |||||
| Avg | 391.5M | 481.1M | |||||
| Low | 370.6M | 445.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 40.2% | 34.9% | |||||
| Avg | 34.2% | 22.9% | |||||
| Low | 27.0% | 13.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.21 | 0.48 | |
| Avg | 0.12 | 0.35 | |
| Low | 0.06 | 0.17 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 6,448.2% | 304.2% | |
| Avg | 3,625.7% | 196.3% | |
| Low | 1,733.5% | 39.4% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.